1. Home
  2. MUX vs XERS Comparison

MUX vs XERS Comparison

Compare MUX & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo McEwen Mining Inc.

MUX

McEwen Mining Inc.

HOLD

Current Price

$23.88

Market Cap

1.6B

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$5.88

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MUX
XERS
Founded
1979
2005
Country
Canada
United States
Employees
1432
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.1B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MUX
XERS
Price
$23.88
$5.88
Analyst Decision
Strong Buy
Buy
Analyst Count
4
6
Target Price
$26.63
$10.83
AVG Volume (30 Days)
913.5K
1.6M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
N/A
Revenue
N/A
$49,590,000.00
Revenue This Year
$37.86
$34.37
Revenue Next Year
$31.10
$22.86
P/E Ratio
N/A
N/A
Revenue Growth
N/A
142.67
52 Week Low
$7.15
$4.07
52 Week High
$29.70
$10.08

Technical Indicators

Market Signals
Indicator
MUX
XERS
Relative Strength Index (RSI) 54.83 47.38
Support Level $22.96 $5.76
Resistance Level $24.88 $7.21
Average True Range (ATR) 1.18 0.24
MACD 0.50 0.05
Stochastic Oscillator 62.88 19.85

Price Performance

Historical Comparison
MUX
XERS

About MUX McEwen Mining Inc.

McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: